BrainsWay Ltd. develops and sells noninvasive neurostimulation treatments for mental health disorders in the United States and internationally. It offers Deep Transcranial Magnetic Stimulation platform technology for the treatment of major depressive disorders, anxious and late-life depression, obsessive-compulsive disorders, smoking addiction, bipolar disorders, post-traumatic stress disorders, schizophrenia, Alzheimer's disease, autism, chronic pain, multiple sclerosis, post stroke rehabilitation, and Parkinson's diseases. The company serves doctors, hospitals, and medical centers in the field of psychiatry. The company was founded in 2003 and is headquartered in Jerusalem, Israel. Show more
16 Hartum St, Jerusalem, 9777516, Israel
Market Cap
595.8M
52 Wk Range
$5.00 - $17.35
Previous Close
$14.88
Open
$14.70
Volume
223,593
Day Range
$14.50 - $15.04
Enterprise Value
631M
Cash
69.13M
Avg Qtr Burn
-759K
Insider Ownership
6.04%
Institutional Own.
29.96%
Qtr Updated
12/31/25
Only showing assets and stage. See catalyst data with a free or premium account. Unlock more data with a free account.
| Drug & Indication | Stage & Event | Catalyst Date |
|---|
